Cost of Revenue: Key Insights for Pfizer Inc. and Veracyte, Inc.

Cost of Revenue Trends: Pfizer Inc. vs. Veracyte, Inc.

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. Over the past decade, Pfizer Inc. and Veracyte, Inc. have demonstrated contrasting trajectories in their cost of revenue. Pfizer, a global pharmaceutical giant, saw its cost of revenue surge by approximately 210% from 2014 to 2023, peaking in 2022. This reflects its expansive operations and significant investments in research and development. In contrast, Veracyte, a smaller biotech firm, experienced a more modest increase of around 580% over the same period, indicative of its growth phase and scaling operations. Notably, 2021 marked a pivotal year for both companies, with Pfizer's costs tripling, likely due to pandemic-related activities, while Veracyte's costs doubled, underscoring its expanding market presence. These insights highlight the dynamic nature of cost management in the pharmaceutical and biotech industries.